

## GRAPHICS

### Risk stratification schema for localized prostate cancer, according to the National Comprehensive Cancer Network (NCCN)

Risk group	Clinical/pathologic features
Very low	<ul style="list-style-type: none"> <li>▪ T1c AND</li> <li>▪ Grade group 1 AND</li> <li>▪ PSA &lt;10 ng/mL AND</li> <li>▪ Fewer than 3 prostate biopsy fragments/cores positive, ≤50% cancer in each fragment/core AND</li> <li>▪ PSA density &lt;0.15 ng/mL/g</li> </ul>
Low	<ul style="list-style-type: none"> <li>▪ T1 to T2a AND</li> <li>▪ Grade group 1 AND</li> <li>▪ PSA &lt;10 ng/mL AND</li> <li>▪ Does not qualify for very low risk</li> </ul>
Favorable intermediate	<ul style="list-style-type: none"> <li>▪ No high or very high risk features</li> <li>▪ No more than one intermediate risk factor:               <ul style="list-style-type: none"> <li>• T2b to T2c OR</li> <li>• Grade group 2 or 3</li> <li>• PSA 10 to 20 ng/mL</li> </ul> </li> </ul> <p>AND</p> <ul style="list-style-type: none"> <li>▪ Grade group 1 or 2</li> </ul> <p>AND</p> <ul style="list-style-type: none"> <li>▪ Percentage of positive biopsy cores &lt;50%</li> </ul>
Unfavorable intermediate	<ul style="list-style-type: none"> <li>▪ No high or very high risk features</li> <li>▪ Two or three of the intermediate risk factors:               <ul style="list-style-type: none"> <li>• T2b to T2c</li> <li>• Grade group 2 or 3</li> <li>• PSA 10 to 20 ng/mL</li> </ul> </li> </ul> <p>AND/OR</p> <ul style="list-style-type: none"> <li>▪ Grade group 3</li> </ul> <p>AND/OR</p> <ul style="list-style-type: none"> <li>▪ ≥50% of positive biopsy cores</li> </ul>
High	<ul style="list-style-type: none"> <li>▪ No very high risk features</li> </ul> <p>AND</p> <ul style="list-style-type: none"> <li>▪ T3a OR</li> <li>▪ Grade group 4 or 5 OR</li> <li>▪ PSA &gt;20 ng/mL</li> </ul>

Very high	<ul style="list-style-type: none"><li>■ T3b to T4 OR</li><li>■ Primary Gleason pattern 5 OR</li><li>■ Two or three high-risk features OR</li><li>■ &gt;4 cores with Grade group 4 or 5</li></ul>
-----------	--

PSA: prostate-specific antigen.

---

*Adapted from: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Prostate Cancer. Version 4.2018.*

---

Graphic 118962 Version 4.0

## ISUP grade group classification system

Grade group	Gleason score and pattern
1	Grade 6 (3+3)
2	Grade 7 (3+4)
3	Grade 7 (4+3)
4	Grade 8 (4+4, 3+5, or 5+3)
5	Grade 9 or 10 (4+5, 5+4, or 5+5)

ISUP: International Society of Urological Pathology.

---

*Adapted from: Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol 2016; 40:244.*

---

Graphic 107132 Version 2.0